for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

60.03USD

Change

-0.61(-1.01%)

Volume

1,659,301

Today's Range

59.95

 - 

60.74

52 Week Range

45.77

 - 

68.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
60.64
Open
60.39
Volume
1,659,301
3M AVG Volume
215.33
Today's High
60.74
Today's Low
59.95
52 Week High
68.34
52 Week Low
45.77
Shares Out (MIL)
2,254.00
Market Cap (MIL)
136,971.60
Forward P/E
--
Dividend (Yield %)
2.96

Next Event

Dividend For BMYMP.PK - 0.5000 USD

Latest Developments

More

Bristol-Myers Squibb Co Says U.S. Food And Drug Administration Accepts For Priority Review Applications For Opdivo In Combination With Cabometyx In Advanced Renal Cell Carcinoma

NIH Launches Phase 3 Safety, Efficacy Trial Of 3 Immune Modulator Drugs In Hospitalized Adults With COVID-19

Bristol Myers Squibb Presents Positive Late-Breaking Data From Phase 3 True North Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14

NEW YORK, NY

10016-8367

United States

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

David V. Elkins

Executive Vice President and Chief Financial Officer Member of the Leadership Team

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President Member of the Leadership Team

Sandra Leung

Executive Vice President, General Counsel

John E. Elicker

Executive Vice President of Investor Relations

Key Stats

1.83 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

20.8K

2018

22.6K

2019

26.1K

2020(E)

42.0K
EPS (USD)

2017

3.010

2018

3.980

2019

4.690

2020(E)

6.272
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.93
Price To Book (MRQ)
2.79
Price To Cash Flow (TTM)
22.78
Total Debt To Equity (MRQ)
95.07
LT Debt To Equity (MRQ)
85.25
Return on Investment (TTM)
-0.72
Return on Equity (TTM)
-0.59

Latest News

Latest News

NIH tests therapies to help cut hospital stays for COVID-19 patients

The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.

Bristol Myers' Opdivo succeeds in late-stage lung cancer trial

Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage trial. Significantly more non-small cell lung cancer (NSCLC) patients receiving...

Bristol Myers' Opdivo succeeds in late-stage lung cancer trial

Bristol Myers Squibb Co said on Wednesday its blockbuster cancer immunotherapy, Opdivo, met the main goal of pathologic complete response, or the absence of cancer cells, in a late-stage study in patients with a type of lung cancer.

Bristol Myers expands heart drug business with $13 billion deal for MyoKardia

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

Bristol-Myers to buy heart drugs developer MyoKardia for about $13 bln

U.S. drugmaker Bristol-Myers Squibb Co said on Monday it would buy heart drugs developer MyoKardia Inc for about $13 billion.

BUZZ-Dr Reddy's soars 9% after settling Revlimid dispute

** India's Dr Reddy's Laboratories Ltd jumps 9% to a record high after drugmaker settles patent litigation with Celgene, a unit of U.S.-based Bristol-Myers Squibb Co

UPDATE 2-Bristol Myers lifts annual profit view on hopes of pickup in patient visits

Bristol Myers Squibb Co on Thursday raised its annual profit forecast as it predicted a recovery in sales of its hospital-administered drugs, which had taken a hit to demand as patients avoided doctors' offices due to the COVID-19 pandemic.

Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors

Bristol Myers Squibb Co raised its annual profit forecast on Thursday on hopes of a recovery in demand for its hospital-administered drugs, which had dropped as patients stayed away from doctors' offices due to the COVID-19 pandemic.

BRIEF-Dragonfly Therapeutics Announces Research Collaboration With Bristol Myers Squibb

* DRAGONFLY THERAPEUTICS ANNOUNCES NEW RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB TO DEVELOP NOVEL THERAPEUTIC CANDIDATES FOR MULTIPLE SCLEROSIS AND NEURO-INFLAMMATION TARGET

BRIEF-Agios And Royalty Pharma Announce $255 Mln Purchase Agreement For IDHIFA Royalty

* AGIOS AND ROYALTY PHARMA ANNOUNCE $255 MILLION PURCHASE AGREEMENT FOR IDHIFA® ROYALTY

BRIEF-Bristol-Myers Squibb Says Declared Quarterly Dividend Of Forty-Five Cents Per Share On $.10 Par Value Common Stock Of Corp

* BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY-FIVE CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK OF CORPORATION Source text for Eikon: Further company coverage:

BRIEF-Jounce Therapeutics Regains Worldwide Rights To JTX-8064 From Bristol Myers Squibb

* JOUNCE THERAPEUTICS REGAINS WORLDWIDE RIGHTS TO JTX-8064 FROM BRISTOL MYERS SQUIBB

BRIEF-Bristol-Myers - New Data Reinforce Durable Clinical Responses Of Orencia In Early Rheumatoid Arthritis

* NEW DATA REINFORCE IMPROVED AND DURABLE CLINICAL RESPONSES OF ORENCIA IN MODERATE-TO-SEVERE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH AUTOANTIBODIES LINKED TO MORE SEVERE DISEASE

Bristol Myers' treatment succeeds in late-stage bowel disease study

U.S. drugmaker Bristol Myers Squibb Co said on Tuesday its treatment Zeposia, which it gained through its $74 billion buyout of Celgene last year, met the main goals of a late-stage study testing it in patients with an inflammatory bowel disease.

BRIEF-Bristol Myers Announces Results From Phase 3 Zeposia Study In Ulcerative Colitis

* BRISTOL MYERS - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRUE NORTH TRIAL EVALUATING ZEPOSIA IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

BRIEF-Bristol Myers Squibb Reports Commercial Launch Of Zeposia For Multiple Sclerosis

* BRISTOL MYERS SQUIBB ANNOUNCES COMMERCIAL LAUNCH AND AVAILABILITY OF ZEPOSIA® (OZANIMOD), A NEW ORAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-U.S. FDA Approves Opdivo, Yervoy With Limited Chemotherapy As First-Line Treatment Of Metastatic Or Recurrent Non-Small Cell Lung Cancer

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINED WITH LIMITED CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC OR RECURRENT NON-SMALL CELL LUNG CANCER

BRIEF-Repare Therapeutics Enters Into Research Collaboration With Bristol Myers Squibb

* REPARE THERAPEUTICS - ENTERED INTO EXCLUSIVE, WORLDWIDE RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB

BRIEF-European Medicines Agency Validates Bristol Myers Squibb's Applications For Idecabtagene Vicleucel And Cc-486

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL MYERS SQUIBB’S APPLICATIONS FOR IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) AND CC-486 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Bristol-Myers Squibb Announced Presentation Of Data Across Its Hematology Portfolio At EHA Annual Congress

* BRISTOL-MYERS SQUIBB CO - ANNOUNCED PRESENTATION OF DATA ACROSS ITS HEMATOLOGY PORTFOLIO AT EHA ANNUAL CONGRESS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up